Atezolizumab

Chemoimmunotherapy extended PFS compared with chemotherapy for patients with extensive-stage small cell lung cancer and ECOG performance status of 2 or 3, according to retrospective study results.

CHICAGO — The addition of atezolizumab to cabozantinib failed to improve clinical outcomes for patients with metastatic renal cell carcinoma who experienced progression on or after immune checkpoint inhibitor therapy, study results showed.

CHICAGO — Adding talazoparib to atezolizumab as maintenance treatment after front-line chemoimmunotherapy significantly lengthened PFS among adults with SLFN11-positive extensive-stage small cell lung cancer, according to a phase 2 study.

CHICAGO — Individuals with high-risk hepatocellular carcinoma undergoing curative-intent procedures did not experience clinically meaningful deterioration in quality of life or function after adjuvant therapy, phase 3 study results showed.

In this video, Daneng Li, MD, a medical oncologist at City of Hope, discussed results from the Phase 3 IMbrave050 trial presented at American Association for Cancer Research Annual Meeting.

Glasgow prognostic score appeared associated with survival among patients with small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide, according to study results.

In this video, Thomas Marron, MD, PhD, discussed results from the phase 3 IMbrave050 study, presented at American Association for Cancer Research Annual Meeting.

In this video, Ahmed Kaseb, MD, CMQ, discussed results from the phase 3 IMbrave050 trial, presented at American Association for Cancer Research Annual Meeting.

In this video, James Cleary, MD, PhD, a medical oncologist at Dana-Farber Cancer Institute, discussed results from the phase 3 IMbrave050 trial, presented at American Association for Cancer Research Annual Meeting.

Adjuvant treatment with atezolizumab and bevacizumab extended RFS compared with active surveillance among patients with hepatocellular carcinoma, according to study findings presented at AACR Annual Meeting.